Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
24.33 USD -0.30 ( 1.22%)
Last update at 2026-11-13T21:00:00Z
VOLUME
2028573
Market Cap
3226.88M
P/E
28.67

Momentum Score

…

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
23.45
Low
24.65
High
52 Week Price Range
29.45
Low
60.91
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Veracyte is a genomics diagnostics company that develops and commercializes tests to improve diagnosis and treatment decisions in oncology and other areas, notably thyroid, lung and prostate disease. Long-term growth may be supported by wider clinical adoption of its existing test portfolio, international expansion, and stronger guideline and payer acceptance. The company appears positioned to translate clinical validation into recurring, service-based revenue as physicians integrate molecular diagnostics into care pathways.
Key investment risks include reimbursement and regulatory uncertainty, competition from other molecular and in-house tests, and execution risk in scaling commercial operations and reaching sustained profitability.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
24.63
Dividend Yield
-
Revenue TTM
561.90M
Revenue Per Share
7.08
Gross Profit TTM
414.44M
Debt / Equity
0.03
ROE
8.77%
Net Debt
-322.92M
ROCE
5.07%
Diluted EPS TTM
1.40

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 68.20M 25.74M -76.61M -36.43M -81.65M
Net income 66.35M 24.14M -74.40M -36.56M -75.56M
Selling general administrative 110.78M 178.27M 157.63M 76.52M 101.35M
Selling and marketing expenses 100.17M 27.77M 26.60M 97.56M 79.84M
Gross profit 360.05M 298.14M 248.15M 194.95M 145.11M
Reconciled depreciation 21.41M 23.46M 27.41M 25.93M 19.59M
Ebit 68.20M 25.75M -76.60M -41.08M -81.90M
Ebitda 89.62M 49.20M -49.41M -15.15M -62.31M
Depreciation and amortization 21.41M 23.46M 27.19M 25.93M 19.59M
Non operating income net other - - - 4.65M 0.25M
Operating income 74.15M 16.14M -85.80M -41.08M -81.90M
Other operating expenses 443.00M 429.62M 446.85M 337.62M 301.42M
Interest expense 0.00M 0.00M 0.01M -4.65M 0.24M
Tax provision 1.85M 1.61M 0.37M 0.13M -6.09M
Interest income 12.72M 11.15M 5.67M 1.97M 0.14M
Net interest income 12.72M 11.15M 5.65M 1.77M -0.11M
Income tax expense 1.85M 1.61M -2.21M 0.13M -6.09M
Total revenue 517.14M 445.76M 361.05M 296.54M 219.51M
Total operating expenses 285.89M 282.00M 333.94M 236.03M 227.02M
Cost of revenue 157.10M 147.62M 112.90M 101.58M 74.40M
Total other income expense net -5.95M 9.60M 9.18M 4.65M 0.25M
Net income from continuing ops 66.35M 24.14M -49.95M -36.56M -75.56M
Net income applicable to common shares - - - -36.56M -75.56M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1406.02M 1300.04M 1137.82M 1156.42M 1187.83M
Intangible assets 89.15M 102.30M 88.59M 174.87M 202.73M
Other current assets 10.28M 14.55M 7.96M 11.47M 17.22M
Total liab 96.44M 124.07M 93.72M 81.22M 91.31M
Total stockholder equity 1309.58M 1175.97M 1044.10M 1075.20M 1096.51M
Deferred long term liab - - - 4.53M 5.59M
Other current liab 50.13M 60.83M 41.19M 44.02M 42.39M
Common stock 0.08M 0.08M 0.07M 0.07M 0.07M
Capital stock 0.08M 0.08M 0.07M 0.07M 0.07M
Retained earnings -377.63M -443.98M -468.12M -393.72M -357.16M
Other liab - - - 7.56M 13.06M
Good will 767.15M 745.80M 702.98M 695.89M 707.90M
Other assets - -33.98M 0.00M 6.17M 2.95M
Cash 362.58M 239.09M 216.45M 154.25M 173.20M
Total current liabilities 59.94M 78.63M 61.24M 62.61M 64.15M
Current deferred revenue 1.16M 1.67M 2.01M 2.61M 4.65M
Net debt -322.92M -188.35M -203.82M -139.53M -154.34M
Short term debt 4.05M 7.50M 5.11M 4.07M 4.76M
Short long term debt - - - - 1.13M
Short long term debt total 39.65M 50.74M 12.63M 14.72M 18.85M
Other stockholder equity 1695.34M 1655.96M 1536.17M 1500.19M 1468.68M
Property plant equipment - - - 30.86M 31.14M
Total current assets 488.38M 372.27M 285.62M 248.64M 243.10M
Net tangible assets - - - 379.31M 185.88M
Short term investments 50.31M 50.35M 0.00M 24.61M -
Net receivables 44.66M 46.52M 45.08M 44.02M 41.46M
Inventory 20.55M 21.75M 16.13M 14.29M 11.22M
Accounts payable 4.59M 8.63M 12.94M 11.91M 12.36M
Accumulated other comprehensive income -8.21M -36.09M -24.02M -31.35M -15.08M
Common stock total equity - - - 0.07M 0.07M
Retained earnings total equity - - - -393.72M -357.16M
Non currrent assets other 2.55M 8.53M 5.97M 6.17M 2.95M
Non current assets total 917.64M 927.77M 852.20M 907.79M 944.72M
Capital lease obligations 39.65M 50.74M 12.63M 14.72M 17.73M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 3.31M -56.27M -8.82M -20.84M 3.00M
Change to liabilities - - - 0.15M 5.16M
Total cashflows from investing activities -9.21M -56.27M 15.11M -29.39M -739.21M
Net borrowings - 0.00M 0.00M -1.28M -1.28M
Total cash from financing activities -4.22M 4.90M 2.84M 3.49M 596.32M
Change to operating activities - - - -9.03M 9.10M
Net income 66.35M 24.14M -74.40M -36.56M -75.56M
Change in cash 123.59M 23.30M 62.33M -18.95M -176.02M
Begin period cash flow 240.63M 217.33M 155.00M 173.95M 349.97M
End period cash flow 364.23M 240.63M 217.33M 155.00M 173.95M
Total cash from operating activities 136.31M 75.10M 44.22M 7.54M -31.62M
Issuance of capital stock - - 0.00M 0.00M 593.82M
Depreciation 21.41M 23.46M 27.19M 25.93M 19.59M
Other cashflows from investing activities -2.85M - - - -736.83M
Change to inventory -2.86M -5.87M -1.69M -3.01M -1.46M
Change to account receivables -0.71M -6.41M 3.89M 1.10M -8.57M
Sale purchase of stock - - -6.74M 7.94M 11.53M
Other cashflows from financing activities -18.30M -15.09M 2.84M -3.17M 2.50M
Change to netincome - - - 27.62M 26.39M
Capital expenditures 9.68M 11.29M 9.96M 8.55M 5.38M
Change receivables - - - -4.50M -8.57M
Cash flows other operating - - - -2.10M 4.69M
Cash and cash equivalents changes - - - -18.36M -174.51M
Change in working capital -2.30M -20.96M -3.69M -16.38M 4.22M
Stock based compensation 43.60M 36.25M 33.14M 26.73M 22.52M
Other non cash items 7.82M 12.45M 65.83M 7.68M 3.87M
Free cash flow 126.63M 63.81M 34.26M -1.01M -37.00M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
VCYT
Veracyte Inc
-0.30
1.22%
24.33 28.67 22.12 5.74 2.38 5.10 20.94
TMO
Thermo Fisher Scientific Inc
0.78
0.11%
700.22 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation
0.86
0.37%
233.02 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd
-0.28
1.14%
24.63 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd
-1.12
4.41%
24.28 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

Veracyte Inc

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

6000 Shoreline Court, South San Francisco, CA, United States, 94080

650 243 6300

755

Name Title Year Born
Ms. Bonnie H. Anderson Co-Founder & Exec. Chairwoman 1958
Mr. Marc A. Stapley CEO & Director 1970
Ms. Rebecca Chambers Exec. VP & CFO 1978
Dr. Giulia C. Kennedy Ph.D. Global Chief Scientific Officer & Chief Medical Officer 1959
Dr. Tina S. Nova Ph.D. Pres of CLIA U.S. Bus. 1954
Ms. Beverly Jane Alley CPA VP & Corp. Controller 1963
Mr. Jonathan Wygant VP & Chief Accounting Officer 1971
Mr. Steven French Sr. VP & Chief Information Officer NA
Ms. Annie McGuire Sr. VP & Gen. Counsel 1980
Ms. Tracy Morris VP of Global Corp. Communications NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…